Ocular oncology: advances in retinoblastoma, uveal melanoma and conjunctival melanoma

Vasalaki, Marina; Fabian, Ido Didi; Reddy, M. Ashwin; Cohen, Victoria M L; Sagoo, Mandeep S.

doi:10.1093/bmb/ldw053

Cited by 25 publications

(25 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the advancements in its treatment and diagnosis, UM remains a challenge because appropriate treatment does not prevent the development of metastases in some patients (17) . Moreover, when the tumor is very large, brachytherapy is insufficient for reducing the lesion, and enucleation is necessary for some patients (2) .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of ranibizumab and amfenac on the functional abilities and radiosensitivity of uveal melanoma cells

Bravo-Filho¹,

Logan²,

Zoroquiaín³

et al. 2019

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

To evaluate the effects of ranibizumab and amfenac in human uveal melanoma cell lines and to explore the ability of these compounds to sensitize uveal melanoma cells to radiation therapy. Methods: The 92.1 human uveal melanoma cell line was cultured and subjected to the proposed treatment (ranibizumab, amfenac, and a combination of both). Proliferation, migration, and invasion assays of the 92.1 uveal melanoma cell line were assessed after pretreatment with ranibizumab (125 µg/mL), amfenac (150 nM), or a combination of both. In addition, proliferation rates were assessed after treatment with ranibizumab and amfenac, and the cells were subsequently exposed to various radiation doses (0, 4, and 8 Gy). Results: Proliferation assay: cells treated with a combination of ranibizumab and amfenac had lower proliferation rates than controls (p=0.016) and than those treated with only ranibizumab (p=0.033). Migration assay: a significantly lower migration rate was observed in cells treated with amfenac than the control (p=0.014) and than those treated with ranibizumab (p=0.044). Invasion assay: there were no significant differences among the studied groups. Irradiation exposure: in the 4 Gy dose group, there were no significant differences among any groups. In the 8 Gy dose group, treatment with ranibizumab, amfenac, and their combination prior to application of the 8 Gy radiation led to a marked reduction in proliferation rates (p=0.009, p=0.01, and p=0.034, respectively) compared with controls. Conclusion: Combination of ranibizumab and amfenac reduced the proliferation rate of uveal melanoma cells; however, only amfenac monotherapy significantly decreased cell migration. The radiosensitivity of the 92.1 uveal melanoma cell line increased following the administration of ranibizumab, amfenac, and their combination. Further investigation is warranted to determine if this is a viable pretreatment strategy to render large tumors amenable to radiotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Despite the recent progress in treatment for these tumors, the mortality rate remains high (1) . Furthermore, some tumors are too large on presentation to qualify for plaque radiation therapy, which is the standard treatment (2) . Therefore, there is a need for alternative treatment options.…”

Section: Introductionmentioning

confidence: 99%

Effects of ranibizumab and amfenac on the functional abilities and radiosensitivity of uveal melanoma cells

Bravo-Filho¹,

Logan²,

Zoroquiaín³

et al. 2019

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

show abstract

“…Uveal melanoma and retinoblastoma are the most common intraocular malignancies in adults and children, respectively [20]. Uveal melanoma, a malignant cancer, can occur anywhere in the uveal tract, including choroid, ciliary body and iris, which affects 4.9 people per million in the United States [21].…”

Section: Discussionmentioning

confidence: 99%

Comparative analysis of RNA-sequencing in intraocular tumors

Yang¹,

Mei²

2019

Preprint

View full text Add to dashboard Cite

Background: Intraocular tumors are a class of serious diseases which may cause blindness and disability. This study aims to explore the underlying mechanisms of gene regulation in intraocular tumors.Methods: In this study, we firstly adopted RNA-sequencing technology to screen the differentially expressed genes in OCM-1 and Y79 cells compared with HRECs.Results: We found 8424 differentially expressed genes (4665 downregulated and 3759 upregulated) in OCM-1 cells compared with HRECs cells, and 7486 differentially expressed genes (4250 downregulated and 3236 upregulated) in Y79 cells compared with HRECs cells. In addition, the GO (Gene Ontology) terms was used to predict the potential functions of these differentially expressed genes and KEGG (Kyoto Encyclopedia of Genes and Genomes) was used to analyze the potential functions of these genes in the pathways. Furthermore, we identified the Top differentially expressed genes by using qRT-PCR assay in intraocular tumors. Conclusions: Here, we fully exposed the differentially expressed genes in intraocular tumor cell lines, which will improve understanding for gene regulation in intraocular tumors.

show abstract

“…As the most frequent (85%) primary intraocular malignancy arising in adults, uveal melanoma (UVM), which is a clinically distinct and speci cally lethal subset of melanoma deriving from eye melanocytes [2]. The large majority of UVM arises from the uvea (95%), comprising the posterior uvea (choroid 90% and ciliary body 5%) and the anterior uvea (iris 5%) of eye [3].…”

Section: Introductionmentioning

confidence: 99%

CIB1 as a potential diagnosis and prognosis biomarker in uveal melanoma

Wang

Liu

Guo

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundUveal melanoma (UVM) is the most common primary intraocular tumor in adults. However, identification of the effective biomarker for the diagnosis and treatment of UVM remain to be explored. Calcium and integrin-binding protein 1 (CIB1) is emerging as an important mediator in carcinogenesis and tumor progression. In the present study, we aim to determine the contribution of CIB1 in the diagnosis of UVM.MethodsImmumohistochemical staining is used to detect the CIB1 expression level, while Gene Expression Profiling Interactive Analysis 2 (GEPIA2) and UALCAN online tools were used to further analyze patient survival and CIB1 correlation genes in UVM. Integrative analysis using STRING and GeneMANIA predicted the correlated genes with CIB1 in UVM.ResultsTo the best of our knowledge the novel observations identified in the present study reveal that CIB1 expression level in UVM was significantly enhanced when compared with that in paracancerous tissues. A higher CIB1 expression level resulted in a significant worse disease free survival as well as overall survival. Moreover, survival probability of patients with UVM was associated with body weight and gender of the the patients. The correlated genes with CIB1 in UVM, and the similarity of the genes in UVM expression and survival heatmap was verified. Furthermore, Gene ontology enrichment analysis revealed that CIB1 and its correlated genes are significantly enriched in ITGA2B-ITGB3-CIB1 complex, regulation of intracellular protein transport and regulation of ion transport.ConclusionsTaken together, our novel findings suggested that CIB1 might be a potential diagnostic predictor for UVM, and might contribute to the potential strategy for UVM treatment by targeting CIB1.# These authors contributed equally to this work

show abstract

Ocular oncology: advances in retinoblastoma, uveal melanoma and conjunctival melanoma

Abstract: Introduction/background: Retinoblastoma, uveal and conjunctival melanomas are important malignancies within the remit of ocular oncology. Outlined are the diagnostic features and management principles, as well as advancements in the field and current challenges.

Cited by 25 publications

References 68 publications

Effects of ranibizumab and amfenac on the functional abilities and radiosensitivity of uveal melanoma cells

Effects of ranibizumab and amfenac on the functional abilities and radiosensitivity of uveal melanoma cells

Comparative analysis of RNA-sequencing in intraocular tumors

CIB1 as a potential diagnosis and prognosis biomarker in uveal melanoma

Contact Info

Product

Resources

About